"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
| Descriptor ID |
D015507
|
| MeSH Number(s) |
D26.371
|
| Concept/Terms |
Drugs, Investigational- Drugs, Investigational
- Investigational New Drugs
- Drugs, Investigational New
- New Drugs, Investigational
- Investigational Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".
This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.
-
The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. PLoS One. 2022; 17(2):e0262109.
-
Toxicity and costs of toxicity associated with new cancer drugs: international implications. J Clin Oncol. 2014 Nov 10; 32(32):3591-2.
-
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18.
-
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013 May-Jun; 27(3):280-6.
-
Developing treatments for female sexual dysfunction. Clin Pharmacol Ther. 2011 Jan; 89(1):137-41.
-
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1726-36.
-
Investigational developments for the treatment of progesterone-dependent diseases. Expert Opin Investig Drugs. 2008 Apr; 17(4):469-79.
-
TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs. 2005 Aug; 14(8):1047-54.
-
Technology evaluation: Kahalalide F, PharmaMar. Curr Opin Mol Ther. 2004 Dec; 6(6):657-65.
-
Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis. 2003 Jun; 3(6):338-48.